IL21 and systemic lupus erythematosus: Considering the heterogeneity of lupus patients, the efficacy of anti-IL-21 antibody on Act1-deficient mice implicates that this mouse strain can be further exploited as a specific model for testing anti-IL-21 as a potential therapy for SLE patients with the SNP-D10N Act1 mutation.